Selective internal radiotherapy in Germany: a review of indications and hospital mortality from 2012 to 2019
Background & aim: Selective Internal Radiotherapy (SIRT) is a minimal invasive tumor therapy for hepatocellular carcinoma (HCC), biliary tract cancer (BTC), and liver metastasis of extrahepatic tumors. Comprehensive data on past and current trends of SIRT as well as outcome parameters such as in-hospital mortality and adverse events in Germany are missing.
Methods: We evaluated current clinical developments and outcomes of SIRT in Germany based on standardized hospital discharge data, provided by the German Federal Statistical Office from 2012 to 2019.
Results: A total of 11,014 SIRT procedures were included in the analysis. The most common indication was hepatic metastases (54.3%; HCC: 39.7%; BTC: 6%) with a trend in favor of HCC and BTC over time. Most SIRTs were performed with yttrium-90 (99.6%) but the proportion of holmium-166 SIRTs increased in recent years. There were significant differences in the mean length of hospital stay between ⁹⁰Y (3.67 ± 2 days) and 166Ho (2.9 ± 1.3 days) based SIRTs. Overall in-hospital mortality was 0.14%. The mean number of SIRTs/hospital was 22.9 (SD ± 30.4). The 20 highest case volume centers performed 25.6% of all SIRTs.
Conclusion: Our study gives a detailed insight into indications, patient-related factors, and the incidence of adverse events as well as the overall in-hospital mortality in a large SIRT collective in Germany. SIRT is a safe procedure with low overall in-hospital mortality and a well-definable spectrum of adverse events. We report differences in the regional distribution of performed SIRTs and changes in the indications and used radioisotopes over the years.
Relevance for Patients: SIRT is a safe procedure with very low overall mortality and a well-definable spectrum of adverse events, particularly gastrointestinal. Complications are usually treatable or self-limiting. Acute liver failure is a potentially fatal but exceptionally rare complication. 166Ho has promising beneficial bio-physical characteristics and 166Ho-based SIRT should be further evaluated against ⁹⁰Y-based SIRT as the current standard of care.
[1] Ariel IM. Treatment of Inoperable Primary Pancreatic and Liver Cancer by the Intra-arterial Administration of Radioactive Isotopes (Y90 Radiating Microspheres). Ann Surg 1965;162:267-78.
[2] Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: A State-of-the-art Brachytherapy Treatment for Primary and Secondary Liver Malignancies. Part 1: Technical and Methodologic Considerations. J Vasc Interv Radiol 2006;17:1251-78.
[3] D‘Abadie P, Hesse M, Louppe A, Lhommel R, Walrand S, Jamar F. Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects. Molecules 2021;26:3966.
[4] Biederman DM, Titano JJ, Tabori NE, Pierobon ES, Alshebeeb K, Schwartz M, et al. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin Versus Glass Microspheres. J Vasc Interv Radiol 2016;27:812-21.e2.
[5] Nezami N, Kokabi N, Camacho JC, Schuster DM, Xing M, Kim HS. 90Y Radioembolization Dosimetry Using a Simple Semi-quantitative Method in Intrahepatic Cholangiocarcinoma: Glass Versus Resin Microspheres. Nucl Med Biol 2018;59:22-8.
[6] Cheng B, Villalobos A, Sethi I, Wagstaff W, Galt J, Brandon D, et al. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization. Cardiovasc Intervent Radiol 2021;44:1194-203.
[7] Thompson S, Ballard B, Jiang Z, Revskaya E, Sisay N, Miller WH, et al. 166Ho and 90Y Labeled 6D2 Monoclonal Antibody for Targeted Radiotherapy of Melanoma: Comparison with 188Re Radiolabel. Nucl Med Biol 2014;41:276-81.
[8] Bertolet A, Wehrenberg-Klee E, Bobić M, Grassberger C, Perl J, Paganetti H, et al. Pre-and Post-Treatment Image-based Dosimetry in90Y-Microsphere Radioembolization Using the TOPAS Monte Carlo Toolkit. Phys Med Biol 2021;66:244002.
[9] Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary Tract Cancer. Lancet 2021;397:428-44.
[10] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49.
[11] Wolstenholme J, Fusco F, Gray AM, Moschandreas J, Virdee PS, Love S, et al. Quality of Life in the FOXFIRE, SIRFLOX and FOXFIRE-Global Randomised Trials of Selective Internal Radiotherapy for Metastatic Colorectal Cancer. Int J Cancer 2020;147:1078-85.
[12] Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and Efficacy of 90Y Radiotherapy for Hepatocellular Carcinoma with and without Portal Vein Thrombosis. Hepatology 2008;47:71-81.
[13] EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J Hepatol 2018;69:182-236.
[14] Vogel A, Martinelli E, ESMO Guidelines Committee. Updated Treatment Recommendations for Hepatocellular Carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol 2021;32:801-5.
[15] Voesch S, Bitzer M, Blödt S, Follmann M, Freudenberger P, Langer T, et al. S3-Leitlinie: Diagnostik und Therapie des Hepatozellulären Karzinoms und Biliärer KarzinomeVersion 2.0-Juni 2021, AWMF-Registernummer: 032-053OL [S3-Guideline: Diagnosis and Therapy of Hepatocellular Carcinoma and Biliary Carcinoma Version 2.0-June 2021, AWMF registration number: 032-053OL]. Z Gastroenterol 2022;60:e131-85.
[16] Helmberger T, Pereira PL. Transarterial Radioembolization of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Radiologe 2022;62:234-8.
[17] Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D, et al. Biliary Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Ann Oncol 2016;27:v28-37.
[18] Boehm LM, Jayakrishnan TT, Miura JT, Zacharias AJ, Johnston FM, Turaga KK, et al. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Intrahepatic Cholangiocarcinoma. J Surg Oncol 2015;111:213-20.
[19] Bargellini I, Bozzi E, Lorenzoni G, Boni G, Bianchi F, Traino CA, et al. Role of Transhepatic Arterial Radioembolization in Metastatic Colorectal Cancer. Cardiovasc Intervent Radiol 2022;45:1579-89.
[20] Bibok A, Kis B, Frakes J, Hoffe S, Zhang J, Jain R, et al. Yttrium-90 Radioembolization for Liver-dominant Metastatic Prostate Cancer: A Case Series. J Vasc Interv Radiol 2022;33:1061-5.
[21] Stavrovski T, Pereira P. Role of Interventional Oncology for Treatment of Liver Metastases: Evidence Based Best Practice. Br J Radiol 2022;95:20211376.
[22] Manchec B, Kokabi N, Narayanan G, Niekamp A, Peña C, Powell A, et al. Radioembolization of Secondary Hepatic Malignancies. Semin Intervent Radiol 2021;38:445-52.
[23] Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update. J Hepatol 2022;76:681-93.
[24] Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and Safety of Selective Internal Radiotherapy with Yttrium-90 Resin Microspheres Compared with Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma (SARAH): An Open-label Randomised Controlled Phase 3 Trial. Lancet Oncol 2017;18:1624-36.
[25] Chow PK, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients with Hepatocellular Carcinoma. J Clin Oncol 2018;36:1913-21.
[26] Kolligs FT, Bilbao JI, Jakobs T, Iñarrairaegui M, Nagel JM, Rodriguez M, et al. Pilot Randomized Trial of Selective Internal Radiation Therapy vs. Chemoembolization in Unresectable Hepatocellular Carcinoma. Liver Int 2015;35:1715-21.
[27] Schönfeld I, Kraywinkel K. Epidemiologie des Hepatozellulären Karzinoms in Deutschland [Epidemiology of Hepatocellular Carcinoma in Germany]. Onkologe 2018;24:653-58.
[28] Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective. Front Oncol 2014;4:210.
[29] Braat AJ, Prince JF, van Rooij R, Bruijnen RC, van den Bosch MA, Lam MG. Safety Analysis of Holmium-166 Microsphere Scout Dose Imaging during Radioembolisation Work-up: A Cohort Study. Eur Radiol 2018;28:920-8.
[30] Radosa CG, Radosa JC, Grosche-Schlee S, Zöphel K, Plodeck V, Kühn JP, et al. Holmium-166 Radioembolization in Hepatocellular Carcinoma: Feasibility and Safety of a New Treatment Option in Clinical Practice. Cardiovasc Intervent Radiol 2019;42:405-12.
[31] Saxena A, Meteling B, Kapoor J, Golani S, Danta M, Morris DL, et al. Yttrium-90 Radioembolization is a Safe and Effective Treatment for Unresectable Hepatocellular Carcinoma: A Single Centre Experience of 45 Consecutive Patients. Int J Surg 2014;12:1403-8.
[32] Stubbs RS, Wickremesekera SK. Selective Internal Radiation Therapy (SIRT): A New Modality for Treating Patients with Colorectal Liver Metastases. HPB (Oxford) 2004;6:133-9.
[33] Sangro B, Martínez-Urbistondo D, Bester L, Bilbao JI, Coldwell DM, Flamen P, et al. Prevention and Treatment of Complications of Selective Internal Radiation Therapy: Expert Guidance and Systematic Review. Hepatology 2017;66:969-82.
[34] Lam MG, Banerjee S, Louie JD, Abdelmaksoud MH, IagaruAH, Ennen RE, et al. Root Cause Analysis of Gastroduodenal Ulceration after Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol 2013;36:1536-47.
[35] Alsultan AA, Braat AJ, Smits ML, Barentsz MW, Bastiaannet R, Bruijnen RC, et al. Current Status and Future Direction of Hepatic Radioembolisation. Clin Oncol (R Coll Radiol) 2021;33:106-16.
[36] Van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, et al. SIRFLOX: Randomized Phase III Trial Comparing First-line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients with Metastatic Colorectal Cancer. J Clin Oncol 2016;34:1723-31.
[37] Kennedy AS, Ball D, Cohen SJ, Cohn M, Coldwell DM, Drooz A, et al. Multicenter Evaluation of the Safety and Efficacy of Radioembolization in Patients with Unresectable Colorectal Liver Metastases Selected as Candidates for (90) Y Resin Microspheres. J Gastrointest Oncol 2015;6:134-42.
[38] Riaz A, Awais R, Salem R. Side Effects of Yttrium-90 Radioembolization. Front Oncol 2014;4:198.
[39] Miller FH, Keppke AL, Reddy D, Huang J, Jin J, Mulcahy MF, et al. Response of Liver Metastases after Treatment with Yttrium-90 Microspheres: Role of Size, Necrosis, and PET. AJR Am J Roentgenol 2007;188:776-83.
[40] Parakh S, Gananadha S, Allen R, Yip D. Cholecystitis after Yttrium-90 Resin Microsphere Radioembolization Treatment: Clinical and Pathologic Findings. Asian J Surg 2016;39:144-8.
[41] Piana PM, Gonsalves CF, Sato T, Anne PR, McCann JW, Ad VB, et al. Toxicities after Radioembolization with Yttrium-90 SIR-spheres: Incidence and Contributing Risk Factors at a Single Center. J Vasc Interv Radiol 2011;22:1373-9.
[42] Paprottka PM, Schmidt GP, Trumm CG, Hoffmann RT, Reiser MF, Jakobs TF. Changes in Normal Liver and Spleen Volume after Radioembolization with (90)Y-resin Microspheres in Metastatic Breast Cancer Patients: Findings and Clinical Significance. Cardiovasc Intervent Radiol 2011;34:964-72.
[43] Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for Hepatocellular Carcinoma. J Hepatol 2012;56:464-73.
[44] Robert Koch-Institute. Krebs in Deutschland Für 2017/2018. Berlin: Robert Koch-Institute; 2021.